Group 1 - The core point of the news is that BaiO Saite's stock price dropped by 5% to 71.82 yuan per share, with a trading volume of 1.32 billion yuan and a turnover rate of 5.00%, resulting in a total market capitalization of 32.096 billion yuan [1] - BaiO Saite (Beijing) Pharmaceutical Technology Co., Ltd. is primarily engaged in antibody drug research and preclinical research services, with operations divided into five segments, including gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focusing on oncology and autoimmune diseases [1] Group 2 - According to data from the top ten holdings of funds, Penghua Fund holds BaiO Saite in its portfolio, specifically in the Penghua New Emerging Industries Mixed A Fund (206009), which held 2.307 million shares, accounting for 3.77% of the fund's net value, ranking as the tenth largest holding [2] - The Penghua New Emerging Industries Mixed A Fund has a total scale of 3.215 billion yuan, with a year-to-date return of 9.29% and a one-year return of 49.94%, ranking 1661 out of 8994 and 1568 out of 8199 respectively [2]
百奥赛图股价跌5%，鹏华基金旗下1只基金重仓，持有230.7万股浮亏损失872.06万元